Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Yocum

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Arthritis Research & Therapy|July 2, 2004
Effective use of TNF antagonistsDavid Yocum
Arthritis Research & Therapy|July 2, 2004
Does safety make a difference in selecting the right TNF antagonist?Roy Fleischmann, David Yocum
Arthritis and Rheumatism|March 31, 2006
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trialRene Westhovens, David Yocum, John Han, et al.
Annals of the Rheumatic Diseases|July 10, 2007
A modification of the Omeract RA MRI score for erosions for use with an extremity MRI system with reduced field of viewJane E Freeston, Ewa Olech, David Yocum, et al.
The Journal of Rheumatology|March 7, 2008
Using extremity magnetic resonance imaging to assess and monitor early rheumatoid arthritis: the optimal joint combination to be scanned in clinical practiceEwa Olech, Jane E Freeston, Philip G Conaghan, et al.
Annals of the Rheumatic Diseases|March 30, 2007
Double-blinded infliximab dose escalation in patients with rheumatoid arthritisMahboob U Rahman, Ingrid Strusberg, Piet Geusens, et al.
Current Medical Research and Opinion|July 14, 2007
A multicenter, randomized, open study to evaluate the impact of an electronic data capture system on the care of patients with rheumatoid arthritisJoseph Huffstutter, W David Craig, Gregory Schimizzi, et al.
The Journal of Rheumatology|June 7, 2007
Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0Thasia Woodworth, Daniel E Furst, Rieke Alten, et al.
The Journal of Rheumatology|February 13, 2002
CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritisUrsula Mason, Jose Aldrich, Ferdinand Breedveld, et al.
Science Translational Medicine|September 23, 2011
A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritisKasia Owczarczyk, Preeti Lal, Alexander R Abbas, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Arthritis Research & Therapy|July 2, 2004
Effective use of TNF antagonistsDavid Yocum
Arthritis Research & Therapy|July 2, 2004
Does safety make a difference in selecting the right TNF antagonist?Roy Fleischmann, David Yocum
Arthritis and Rheumatism|March 31, 2006
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trialRene Westhovens, David Yocum, John Han, et al.
Annals of the Rheumatic Diseases|July 10, 2007
A modification of the Omeract RA MRI score for erosions for use with an extremity MRI system with reduced field of viewJane E Freeston, Ewa Olech, David Yocum, et al.
The Journal of Rheumatology|March 7, 2008
Using extremity magnetic resonance imaging to assess and monitor early rheumatoid arthritis: the optimal joint combination to be scanned in clinical practiceEwa Olech, Jane E Freeston, Philip G Conaghan, et al.
Annals of the Rheumatic Diseases|March 30, 2007
Double-blinded infliximab dose escalation in patients with rheumatoid arthritisMahboob U Rahman, Ingrid Strusberg, Piet Geusens, et al.
Current Medical Research and Opinion|July 14, 2007
A multicenter, randomized, open study to evaluate the impact of an electronic data capture system on the care of patients with rheumatoid arthritisJoseph Huffstutter, W David Craig, Gregory Schimizzi, et al.
The Journal of Rheumatology|June 7, 2007
Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0Thasia Woodworth, Daniel E Furst, Rieke Alten, et al.
The Journal of Rheumatology|February 13, 2002
CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritisUrsula Mason, Jose Aldrich, Ferdinand Breedveld, et al.
Science Translational Medicine|September 23, 2011
A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritisKasia Owczarczyk, Preeti Lal, Alexander R Abbas, et al.
Pageof 2